Sarepta Therapeutics (SRPT) PT Lowered to $60 at RBC Capital
Tweet Send to a Friend
RBC Capital lowered its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $60.00 (from $91.00) while maintaining a Outperform rating.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
